Working… Menu
Trial record 46 of 295 for:    IFNA2 AND PEG-interferon alfa-2b

Evaluation of Peginterferon Alfa-2b Monotherapy and Combination With Ribavirin in Participants With Acute Hepatitis C (P03552/MK-4031-137)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00686517
Recruitment Status : Completed
First Posted : May 30, 2008
Results First Posted : January 31, 2012
Last Update Posted : April 5, 2017
Bioikos Ambiente Srl
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.

Brief Summary:
The objective of this study is to evaluate the efficacy of three regimens of pegylated interferon-alfa 2b (PEG-IFN) either as monotherapy or in combination with ribavirin in participants with acute hepatitis C. After 12 weeks of observation from disease onset, participants will receive one of the following regimens: (1) a 24-week course of PEG-IFN monotherapy (PEG-IFN 24); or (2) a 12-week course of PEG-IFN monotherapy (PEG-IFN-12); or (3) a 12-week course of PEG-IFN in combination with ribavirin (PEG-IFN + RVB 12). After the treatment period, participants will enter a 12-month follow-up.

Condition or disease Intervention/treatment Phase
Hepatitis C Biological: Pegylated interferon alfa-2b Drug: Ribavirin Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 130 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open, Randomized, Multicentre Trial to Evaluate Efficacy and Safety of a 24-week Course of PEG-Interferon Alpha-2b Versus a 12-week Course of PEG-Interferon Alpha-2b Alone or Plus Ribavirin in Patients With Acute Hepatitis C
Study Start Date : December 2003
Actual Primary Completion Date : December 2010
Actual Study Completion Date : December 2010

Arm Intervention/treatment
Experimental: PEG-IFN 24
pegylated interferon alpha-2b 1.5 ug/kg/week for 24 weeks
Biological: Pegylated interferon alfa-2b
1.5 ug/kg/week SC for 12 or 24 weeks
Other Name: SCH 54031, PegIntron

Experimental: PEG-IFN 12
pegylated interferon alpha-2b 1.5 ug/kg/week for 12 weeks
Biological: Pegylated interferon alfa-2b
1.5 ug/kg/week SC for 12 or 24 weeks
Other Name: SCH 54031, PegIntron

Experimental: PEG-IFN + RVB 12
pegylated interferon alpha-2b 1.5 ug/kg/week in combination with ribavirin at the dose of 10.6 mg/kg/day for 12 weeks
Biological: Pegylated interferon alfa-2b
1.5 ug/kg/week SC for 12 or 24 weeks
Other Name: SCH 54031, PegIntron

Drug: Ribavirin
Ribavirin at the dose of 10.6 mg/kg/day for 12 weeks
Other Name: SCH 18908, Rebetol

Primary Outcome Measures :
  1. Number of Participants With Sustained Response (SR) at the End of the 6-month Follow-up Period [ Time Frame: Evaluated at the end of 6 months ]
    SR was defined as serum Hepatitis C Virus (HCV RNA) level at the end of 6-month follow-up below 15 IU/mL.

Secondary Outcome Measures :
  1. Virologic Response at the End of Treatment Follow-up (ETR) [ Time Frame: At the end of treatment (either 12 weeks or 24 weeks depending on randomization). ]

    ETR was achieved if serum HCV RNA level at the end of 12 or 24 weeks

    treatment (depending on treatment arm) was <15 IU/mL.

  2. Virologic Response at 12 Months Post-treatment Follow-up (Long-term Response, [LTR]). [ Time Frame: At 12 months post-treatment (treatment period either 12 weeks or 24 weeks depending on randomization). ]
    LTR was obtained if serum HCV RNA level at the end of 12-month follow-up was <15 IU/mL.

  3. Number of Participants Presenting With Alanine Transferase (ALT) Level Normalization [ Time Frame: Evaluated at end of treatment (either 12 weeks or 24 weeks, depending on randomization), at 6-month follow-up visit, or at 12-month follow-up visit. ]
    ALT normalization was used as a measure of biochemical response to treatment. ALT levels were assessed at each study visit by the local laboratory, and efficacy measurements at the end of treatment, at 6 and 12 months post treatment follow-up were reported.

  4. Number of Participants With Rapid Virologic Response (RVR) [ Time Frame: Evaluated at 2 and 4 weeks of treatment ]

    Participants were considered to have RVR if serum HCV RNA level at 2 or 4

    weeks of treatment was below the cut off value of the referring local

    laboratory of each participating site.

  5. Number of Peripheral Blood Mononuclear Cells (PBMCs) [ Time Frame: Treatment Weeks 2, 4, 8, and 12 ]
    Cellular Differentiation Cluster Antigen 8-Positive (CD8+) PBMCs were measured at randomization, Treatment Weeks 2, 4, 8, and 12.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosed with acute hepatitis C virus (HCV).
  • Normal and Elevated serum alanine transferase (ALT) levels
  • Positive serum HCV-RNA.
  • Aged between 18 and 65 years.
  • Negative urine or serum pregnancy test (for women of childbearing potential) documented within the 24-hour period prior to the first dose of the drug. Additionally, all fertile males with partners of childbearing age and females must be using reliable contraception during the study and additionally for participants treated with ribavirin, for 6 months (for woman) and 7 months (for man and his partner) after treatment completion

Exclusion Criteria:

  • Liver disease unrelated to HCV infection
  • Hemoglobin (Hgb) <12g/dL in women and <13g/dL in men; white blood cells (WBC) <3,000/uL; platelets (PLTs) <100,000/ul
  • Women with ongoing pregnancy or who are breast feeding
  • History of severe psychiatric disease, especially depression
  • History of neurologic disease, especially epilepsy
  • History or evidence of symptoms of severe cardiac, gastrointestinal and kidney disease
  • Positive anti-Human Immunodeficiency Virus (HIV) antibodies
  • Positive anti-nuclear antibodies (ANA) and/or Anti-Smooth Muscle Antibody (ASMA) (>1/80)
  • Positive Hepatitis B surface antigen (HBsAg)
  • History of having received any systemic anti-neoplastic or immunomodulatory treatment in the previous 6 months
  • History or other evidence of severe illness or any other conditions which would make the participants, in the opinion of investigator, unsuitable for the study (active drug addict except those under methadone treatment, thalassemic, dyalized included)

Publications of Results:
Layout table for additonal information
Responsible Party: Merck Sharp & Dohme Corp. Identifier: NCT00686517     History of Changes
Other Study ID Numbers: P03552
First Posted: May 30, 2008    Key Record Dates
Results First Posted: January 31, 2012
Last Update Posted: April 5, 2017
Last Verified: March 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description:

Additional relevant MeSH terms:
Layout table for MeSH terms
Interferon alpha-2
Peginterferon alfa-2b
Hepatitis A
Hepatitis C
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Flaviviridae Infections
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Molecular Mechanisms of Pharmacological Action
Immunologic Factors
Physiological Effects of Drugs